Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)
ID: 356963Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356963

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer (STTR) Grant, specifically under the R41/R42 program, aimed at developing innovative devices for the detection of new and existing drugs. This funding opportunity encourages small businesses to create cost-effective, user-friendly technologies that can detect drugs at the point-of-need, such as in emergency departments or harm reduction centers, utilizing target-agnostic methods that provide greater sensitivity and selectivity than traditional detection methods. With a total funding amount of $3 million available to support approximately four to seven projects, applications are due by February 19, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-26-019-Full-Announcement.html
    RFA-DA-26-019.html
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer (STTR) Grant, specifically R41/R42, aimed at developing innovative devices for the detection of new and existing drugs. The funding opportunity encourages applications from small business concerns (SBCs) focused on creating cost-effective, user-friendly technologies that can detect drugs at the point-of-need, such as emergency departments or harm reduction centers. The devices should utilize target-agnostic methods, offering greater sensitivity and selectivity than traditional liquid chromatography-mass spectrometry (LC-MS), which is often too costly and complex for widespread use. Key research areas include developing devices that require minimal training and consumables, achieving sensitivity for detecting drugs in bodily fluids like urine, blood, and sweat within an hour. The notification also outlines application procedures, eligibility requirements, and deadlines, with a total of $3 million available to fund approximately four to seven projects. Successful projects are expected to advance drug detection capabilities and bring innovative technologies to the market, fostering public health through improved drug awareness and timely response to emerging threats. Applications are encouraged to avoid using stigmatizing language regarding substance use disorders, adhering to preferred terms recommended by NIH.
    Similar Opportunities
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)." This initiative invites Small Business Technology Transfer (STTR) grant applications from small business concerns proposing research projects aimed at developing innovative, FDA-regulated medical products to address the urgent needs of patients suffering from opioid and stimulant use disorders. The program is particularly focused on two scientific areas: pharmacotherapeutics and medical therapeutic and diagnostic devices, including software as a medical device, in response to the national crisis of substance use disorders. Grants of up to $300,000 are available, with a submission deadline of February 14, 2025, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-038.html.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)." This initiative aims to support Small Business Technology Transfer (STTR) grant applications focused on developing innovative and accessible solutions to improve health outcomes for individuals affected by non-disordered drug use. The program emphasizes the creation of affordable interventions that can be implemented in community-based care systems, targeting vulnerable populations with limited access to traditional healthcare services. Funding amounts of up to $400,000 for Phase I and $3 million for Phase II are available, with applications due by December 3, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods," aimed at small businesses. This initiative seeks to develop innovative, cost-effective drug detection technologies capable of identifying both known and emerging drugs, such as xylazine and nitazenes, with sensitivity comparable to liquid chromatography-mass spectrometry (LC-MS). The program emphasizes the need for user-friendly devices that can facilitate on-site drug detection, thereby addressing public health challenges related to drug misuse. A total budget of approximately $3 million is available for four to seven grants, with applications due by January 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-018.html.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)" aimed at supporting Small Business Innovation Research (SBIR) proposals. This initiative seeks innovative, accessible, and affordable solutions to address health complications arising from non-disordered drug use, including issues such as hypoxia-related brain injuries from opioid overdoses and cardiovascular problems from stimulant use. The program anticipates a total budget of $2 million for approximately 2-5 awards in Fiscal Year 2025, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Small Business Innovation Research (SBIR) grants aimed at developing regulated therapeutic and diagnostic solutions for patients affected by Opioid Use Disorders (OUD) and Stimulant Use Disorders (StUD). This initiative encourages small businesses to propose research projects focused on the commercialization of novel, FDA-regulated medical products, specifically in the areas of pharmacotherapeutics and medical therapeutic and diagnostic devices, including software solutions. Given the urgent public health crisis highlighted by rising drug overdose fatalities, this funding aims to enhance treatment accessibility and efficacy for affected individuals and communities. Interested applicants can apply for a total funding amount of approximately $3 million, with a submission deadline of February 14, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-021.html.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at small business concerns (SBCs) to develop technologies that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. This initiative, titled "Seeking Products to Address Social Needs impacting SUD," invites applications for Small Business Technology Transfer (STTR) grants under phases I and II, with a total funding amount of $1.3 million available for four awards in FY 2025. The focus is on leveraging innovative technologies, such as telemedicine and mobile health applications, to improve conditions like housing instability and food insecurity that influence SUD outcomes. Interested applicants must comply with specific eligibility criteria and application guidelines, with a submission deadline of March 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) grant applications, inviting eligible U.S. small businesses to submit proposals that include at least one clinical trial. This funding opportunity aims to support research and development projects that align with the scientific missions of participating NIH Institutes and Centers, emphasizing the importance of innovation in health-related technologies. Eligible applicants must be U.S.-based small businesses with majority ownership by U.S. citizens or resident aliens, and the grants provide funding caps of up to $306,872 for Phase I and $2,045,816 for Phase II projects. Interested parties should note that the application deadline is April 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    STTR Solutions to Enable Population Genomic Screening (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Small Business Technology Transfer (STTR) applications aimed at developing innovative solutions for population genomic screening, particularly for common genomic conditions in primary care settings. The initiative seeks to create technologies, services, and educational resources that address barriers to genomic screening, including management, awareness, and referral processes, while promoting community engagement and collaboration between primary care providers and specialized genomic centers. Eligible U.S.-based small businesses can apply for Phase I grants up to $400,000 and Phase II grants up to $2,150,000, with applications due by December 2, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-262.html.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, inviting eligible U.S. small businesses to submit proposals for innovative projects that align with NIH's research and development mission. This funding opportunity, identified as PA-24-247, specifically excludes clinical trials and aims to foster collaboration between small businesses and research institutions to advance technology development in health-related fields. Eligible applicants must be for-profit small businesses based in the U.S., with budget limits set at $306,872 for Phase I and $2,045,816 for Phase II awards. The application deadline is April 5, 2025, with an initial submission date of September 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at supporting small business concerns (SBCs) in developing technologies that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. The initiative seeks innovative products that tackle core social determinants such as housing instability, food insecurity, and personal safety, with an emphasis on integrating technology like telemedicine and health applications to enhance access and reduce treatment barriers for at-risk populations. A total funding amount of $2 million is available, with specific allocations for Phase I and Phase II applications, and the deadline for submission is March 13, 2026, with letters of intent recommended 30 days prior. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-048.html.